Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Cash Flow: 2017-2024

Historic Net Cash Flow for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $288.5 million.

  • BridgeBio Pharma's Net Cash Flow rose 25.16% to -$106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.2 million, marking a year-over-year increase of 304.04%. This contributed to the annual value of $288.5 million for FY2024, which is 1402.42% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Net Cash Flow of $288.5 million as of FY2024, which was up 1,402.42% from -$22.2 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Net Cash Flow high stood at $288.5 million for FY2024, and its period low was -$22.2 million during FY2023.
  • Over the past 3 years, BridgeBio Pharma's median Net Cash Flow value was $20.5 million (recorded in 2022), while the average stood at $95.6 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 207.96% in 2023, then skyrocketed by 1,402.42% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Net Cash Flow (Yearly) stood at -$5.5 million in 2020, then spiked by 782.96% to $37.7 million in 2021, then tumbled by 45.55% to $20.5 million in 2022, then slumped by 207.96% to -$22.2 million in 2023, then skyrocketed by 1,402.42% to $288.5 million in 2024.